The US Food and Drug Administration (FDA) has issued a statement regarding the safety of the drug ranitidine (Zantac®) after the detection of low-levels of contamination.
The FDA and several health regulatory bodies including the Health Canada and the European Medicines Agency are conducting an evaluation on this matter.
The Cayman Islands Health Services Authority (HSA) is aware of the issue and is closely monitoring the evaluation. Once the aforementioned agencies release more information, the HSA will provide an update. In the meantime, the organization is recommending that patients continue taking their ranitidine as prescribed.
18 Jun, 2020
28 Mar, 2020
11 Apr, 2020
17 Jul, 2020